Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 3.74
PTN's Cash to Debt is ranked higher than
51% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.71 vs. PTN: 3.74 )
Ranked among companies with meaningful Cash to Debt only.
PTN' s 10-Year Cash to Debt Range
Min: 1.4  Med: 174.92 Max: No Debt
Current: 3.74
F-Score: 3
Z-Score: -8.00
M-Score: 1646.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -75.87
PTN's Operating margin (%) is ranked lower than
72% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. PTN: -75.87 )
Ranked among companies with meaningful Operating margin (%) only.
PTN' s 10-Year Operating margin (%) Range
Min: -155850  Med: -742.86 Max: -21.25
Current: -75.87
-155850
-21.25
Net-margin (%) -76.43
PTN's Net-margin (%) is ranked lower than
73% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. PTN: -76.43 )
Ranked among companies with meaningful Net-margin (%) only.
PTN' s 10-Year Net-margin (%) Range
Min: -208620  Med: -757.14 Max: -12.64
Current: -76.43
-208620
-12.64
ROE (%) -54.25
PTN's ROE (%) is ranked lower than
79% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.85 vs. PTN: -54.25 )
Ranked among companies with meaningful ROE (%) only.
PTN' s 10-Year ROE (%) Range
Min: -648.65  Med: -150.00 Max: -28.39
Current: -54.25
-648.65
-28.39
ROA (%) -36.66
PTN's ROA (%) is ranked lower than
74% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. PTN: -36.66 )
Ranked among companies with meaningful ROA (%) only.
PTN' s 10-Year ROA (%) Range
Min: -214.29  Med: -91.65 Max: -14.01
Current: -36.66
-214.29
-14.01
ROC (Joel Greenblatt) (%) -6133.21
PTN's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. PTN: -6133.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7728.89  Med: -603.66 Max: -92
Current: -6133.21
-7728.89
-92
Revenue Growth (3Y)(%) -100.00
PTN's Revenue Growth (3Y)(%) is ranked lower than
98% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. PTN: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -26.30 Max: 155.4
Current: -100
-100
155.4
EBITDA Growth (3Y)(%) -37.40
PTN's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. PTN: -37.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PTN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.2  Med: -15.30 Max: 15.3
Current: -37.4
-65.2
15.3
EPS Growth (3Y)(%) -41.20
PTN's EPS Growth (3Y)(%) is ranked lower than
84% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. PTN: -41.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PTN' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.3  Med: -18.30 Max: 5.3
Current: -41.2
-63.3
5.3
» PTN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PTN Guru Trades in Q2 2014

Chuck Royce 35,000 sh (unchged)
» More
Q3 2014

PTN Guru Trades in Q3 2014

Chuck Royce 35,000 sh (unchged)
» More
Q4 2014

PTN Guru Trades in Q4 2014

Chuck Royce 35,000 sh (unchged)
» More
Q1 2015

PTN Guru Trades in Q1 2015

Jim Simons 85,600 sh (New)
Chuck Royce 35,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PTN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.57
PTN's P/B is ranked higher than
83% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. PTN: 1.57 )
Ranked among companies with meaningful P/B only.
PTN' s 10-Year P/B Range
Min: 0.81  Med: 2.58 Max: 205
Current: 1.57
0.81
205
P/S 7.76
PTN's P/S is ranked lower than
75% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. PTN: 7.76 )
Ranked among companies with meaningful P/S only.
PTN' s 10-Year P/S Range
Min: 0.84  Med: 6.71 Max: 31.37
Current: 7.76
0.84
31.37
Current Ratio 7.46
PTN's Current Ratio is ranked higher than
85% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. PTN: 7.46 )
Ranked among companies with meaningful Current Ratio only.
PTN' s 10-Year Current Ratio Range
Min: 1  Med: 3.79 Max: 21.07
Current: 7.46
1
21.07
Quick Ratio 7.46
PTN's Quick Ratio is ranked higher than
88% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. PTN: 7.46 )
Ranked among companies with meaningful Quick Ratio only.
PTN' s 10-Year Quick Ratio Range
Min: 1  Med: 3.74 Max: 21.07
Current: 7.46
1
21.07
Days Sales Outstanding 85.54
PTN's Days Sales Outstanding is ranked lower than
69% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. PTN: 85.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTN' s 10-Year Days Sales Outstanding Range
Min: 0.08  Med: 24.40 Max: 138.11
Current: 85.54
0.08
138.11

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.78
PTN's Price/Net Cash is ranked higher than
93% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. PTN: 1.78 )
Ranked among companies with meaningful Price/Net Cash only.
PTN' s 10-Year Price/Net Cash Range
Min: 0.76  Med: 5.05 Max: 271.11
Current: 1.78
0.76
271.11
Price/Net Current Asset Value 1.63
PTN's Price/Net Current Asset Value is ranked higher than
94% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.29 vs. PTN: 1.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PTN' s 10-Year Price/Net Current Asset Value Range
Min: 0.75  Med: 4.86 Max: 109.38
Current: 1.63
0.75
109.38
Price/Tangible Book 1.60
PTN's Price/Tangible Book is ranked higher than
85% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.08 vs. PTN: 1.60 )
Ranked among companies with meaningful Price/Tangible Book only.
PTN' s 10-Year Price/Tangible Book Range
Min: 0.74  Med: 3.77 Max: 193.57
Current: 1.6
0.74
193.57
Price/Median PS Value 1.12
PTN's Price/Median PS Value is ranked higher than
51% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. PTN: 1.12 )
Ranked among companies with meaningful Price/Median PS Value only.
PTN' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 1.41 Max: 28.07
Current: 1.12
0.17
28.07
Earnings Yield (Greenblatt) (%) -98.69
PTN's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. PTN: -98.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -107.9  Med: 309.40 Max: 31027.6
Current: -98.69
-107.9
31027.6

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 14 5 96 185
EPS($) -0.09 -0.19 0.41 0.36
EPS without NRI($) -0.09 -0.19 0.41 0.36

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PTNA.Germany,
Palatin Technologies Inc was incorporated in Delaware in 1986. The Company is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (wasting syndrome) and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of acute asthma, heart failure, hypertension and other cardiovascular diseases. The Company's main product in development is bremelanotide for the treatment of female sexual dysfunction. It also has drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, dermatologic diseases and inflammatory diseases. It has an exclusive global research collaboration and license agreement with AstraZeneca AB (AstraZeneca) to commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. The Company's main competitors, includes pharmaceutical, biopharmaceutical and biotechnology companies.
» More Articles for PTN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 11 2015
Why Palatin Is Still A Buy Jun 07 2015
Why Palatin Is Still A Buy Jun 05 2015
Palatin Technologies (PTN) Stock Spikes Following FDA Approval of 'Female Viagra' Treatment Jun 05 2015
Roth Capital: Palatin Technologies Still A Buy, Worth $4/Share Jun 05 2015
Shares of a company making a 'female Viagra'-like drug are skyrocketing Jun 05 2015
U.S. FDA panel backs female libido drug, with conditions Jun 04 2015
Palatin Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for... Jun 04 2015
PALATIN TECHNOLOGIES INC Financials May 22 2015
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 13 2015
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results May 13 2015
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results; Teleconference and... May 13 2015
Q3 2015 Palatin Technologies Inc Earnings Release - Before Market Open May 13 2015
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report May 12 2015
Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2015 Results May 08 2015
Palatin Technologies, Inc. To Report Third Quarter Fiscal Year 2015 Results May 08 2015
3 Stocks Under $10 to Trade for Breakouts Apr 21 2015
Palatin Technologies to Present at the 27th Annual ROTH Conference Mar 09 2015
Palatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual... Feb 20 2015
Macrocure (MCUR) in Focus: Stock Falls 5.5% - Tale of the Tape Feb 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK